第二条 提名委员会是董事会下设的专门委员会，经董事会批准后成立。 第三条 提名委员会必须遵守公司章程，在董事会授权的范围内独立行使职 权，并直接向董事会负责。 振德医疗用品股份有限公司 提名委员会工作细则 第一章 总则 第一条 为完善振德医疗用品股份有限公司（以下简称"公司"）治理结构， 优化董事会及高级管理人员组成，协助董事会科学决策，促进经营层高效管理， 根据《中华人民共和国公司法》、《上市公司治理准则》、《上市公司独立董事管理 办法》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关法 律、法规、规范性文件和《振德医疗用品股份有限公司章程》（以下简称"公司 章程"）的规定，公司特设立董事会提名委员会，并制定本工作细则。 第二章 提名委员会的产生与组成 第四条 提名委员会由 3 名委员组成，设召集人 1 名。 第五条 提名委员会委员由董事组成，其中独立董事委员占多数并担任召集 人。 第六条 提名委员会委员由董事会选举产生。召集人由独立董事担任并由提 名委员会的委员按一般多数原则选举产生，负责主持委员会工作。 第七条 提名委员会任期与董事会一致，可以连选连任。在委员任职期间， 如有委员不再 ...

振德医疗用品股份有限公司独立董事 关于第三届董事会第十二次会议相关事项的独立意见 根据《上海证券交易所股票上市规则》、《上市公司独立董事管理 办法》和《公司章程》等有关规定，作为振德医疗用品股份有限公司 （以下简称"公司"）的独立董事，我们对公司第三届董事会第十二 次会议审议的相关事项发表独立意见如下： 经核查，公司第二期员工持股计划的第一个解锁期解锁条件达成， 符合《关于上市公司实施员工持股计划试点的指导意见》等法律法规 以及《第二期员工持股计划（草案）》、《第二期员工持股计划管理 办法》的相关规定，审议、决策程序合法、合规，决议真实有效，不 存在损害公司及全体股东尤其是中小股东利益的情形。我们一致同意 本次解锁条件达成事项。 独立董事签字: 倪崖 李生校 朱茶芬 2023 年 12月 13 日 （本页为振德医疗用品股份有限公司独立董事关于第三届董事会第 十二次会议相关事项的独立意见签署页) 独立董事签字: （以下无正文） (本页为振德医疗用品股份有限公司独立董事关于第三届董事会第 十二次会议相关事项的独立意见签署页) 倪崖 李生校 朱茶芬 2023 年 12 月 13 日 (本页为振德医疗用品股份有限公司 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥903,054,567.59, a decrease of 36.87% compared to the same period last year[5] - Net profit attributable to shareholders was ¥63,155,119.11, down 65.58% year-on-year[5] - The basic earnings per share for the period was ¥0.24, reflecting a decline of 70.37% compared to the previous year[6] - The net profit attributable to shareholders for the year-to-date period was ¥300,521,451.57, a decrease of 33.96% compared to the same period last year[5] - Net profit for the third quarter of 2023 was CNY 308,745,291.11, a decline of 33.3% from CNY 462,971,053.32 in the same quarter of 2022[22] - Total comprehensive income for Q3 2023 was ¥323,240,452.44, down from ¥421,257,460.41 in Q3 2022, representing a decrease of approximately 23.3%[23] - Basic earnings per share for Q3 2023 was ¥1.13, compared to ¥2.02 in Q3 2022, reflecting a decline of about 44.3%[23] Revenue Breakdown - Sales revenue from isolation protective products (masks, protective clothing, etc.) was ¥0.32 billion, a significant drop of 93.39% year-on-year[10] - Excluding isolation protective products, the company's revenue was ¥8.71 billion, a decrease of 7.65% year-on-year[10] - The company achieved a total of ¥5.22 billion in sales from isolation protective products in the first three quarters of 2023, down 69.20% year-on-year[10] - Total operating revenue for the first three quarters of 2023 was CNY 3,209,194,823.07, a decrease of 23.5% compared to CNY 4,197,542,725.56 in the same period of 2022[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,705,279,117.33, a decrease of 2.43% from the end of the previous year[6] - The company's total assets as of the end of the third quarter of 2023 amounted to CNY 7,705,279,117.33, compared to CNY 7,896,933,885.12 at the end of the previous year[18] - Total current assets decreased to ¥3,354,549,722.52 from ¥4,133,980,600.76 year-over-year[16] - The total liabilities of the company were CNY 1,996,011,606.65, a decrease from CNY 2,139,939,039.32 year-over-year[18] - Non-current liabilities decreased to CNY 475,812,759.34 from CNY 621,210,462.53 year-over-year, reflecting a reduction of 23.4%[18] - The company's total equity as of the end of the third quarter of 2023 was CNY 5,709,267,510.68, down from CNY 5,756,994,845.80 at the end of the previous year[18] Cash Flow - The company reported a cash flow from operating activities of ¥262,852,224.14, down 12.89% year-on-year[5] - Cash inflow from operating activities for the first three quarters of 2023 was ¥3,823,930,847.44, down 21.8% from ¥4,888,908,254.18 in the same period of 2022[24] - Net cash flow from operating activities for the first three quarters of 2023 was ¥262,852,224.14, a decrease of 12.9% compared to ¥301,735,384.37 in the previous year[25] - Cash outflow from investing activities for the first three quarters of 2023 totaled ¥1,157,904,356.82, an increase of 31% from ¥884,015,526.28 in the same period of 2022[25] - Net cash flow from investing activities for the first three quarters of 2023 was -¥1,055,233,440.43, worsening from -¥623,768,264.99 in the previous year[25] - Cash inflow from financing activities for the first three quarters of 2023 was ¥585,065,805.00, down 74.6% from ¥2,304,227,074.08 in the same period of 2022[25] - Net cash flow from financing activities for the first three quarters of 2023 was -¥74,313,386.63, compared to ¥623,897,439.24 in the previous year, indicating a significant decline[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,578[13] - Zhejiang Zhend Medical Holdings Co., Ltd. holds 49.82% of shares, with 132,739,480 shares pledged[13] - The top 10 shareholders include Zhejiang Zhend Medical Holdings Co., Ltd. and Xuchang Zhend Landscape Greening Engineering Co., Ltd., with no other significant relationships noted[14] Other Information - The company has not reported any significant new strategies or product developments in the current quarter[15] - The company's financial statements are unaudited for the reporting period[16] - The company has adopted new accounting standards starting in 2023, which may affect the financial statements and related disclosures[26] - The company has a long-term equity investment of ¥72,051,985.97 as of September 30, 2023[16] - Research and development expenses for the first three quarters of 2023 were CNY 110,447,381.62, down 31.3% from CNY 160,613,197.60 in the same period of 2022[21]

4、投资者可于 2023 年 11 月 13 日（星期一）至 11 月 17 日（星 期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明 会上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2023 年 10 月 31 日发布公司 2023 年第三季度报告。为便于广大投资者更全 面深入地了解公司 2023 年三季度经营成果、财务状况，公司计划于 2023 年 11 月 20 日上午 10:00-11:00 举行 2023 年第三季度业绩说明 会，就投资者关心的问题进行交流。 证券代码：603301 证券简称：振德医疗 公告编号：2023-033 振德医疗用品股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2023 年 11 月 20 日（星期一）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址 ...

证券代码：603301 证券简称：振德医疗 公告编号：2023-031 振德医疗用品股份有限公司 2023 年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.75 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/10/30 | － | 2023/10/31 | 2023/10/31 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2023 年 9 月 19 日的 2023 年第一次临时股东大会审议通过。 二、 分配方案 公司根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公 司自律监管指引第 7 号——回购股份》及《公司章程》等有关规定，按照以下公式计算除权 除息开盘参考价： 除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比例） ...

差异化分红事项的核查意见 中信证券股份有限公司 关于振德医疗用品股份有限公司 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为振德医疗用品 股份有限公司（以下简称"振德医疗"或"公司"）2021 年度非公开发行股票的保荐人， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公司自 律监管指引第 7 号——回购股份》《上海证券交易所上市公司自律监管指南第 2 号—— 业务办理》及《公司章程》等有关规定，就振德医疗 2023 年半年度利润分配所涉及的 差异化分红（以下简称"本次差异化分红"）进行了核查，具体情况如下： 一、本次差异化分红的原因 公司于 2022 年 9 月 30 日召开第三届董事会第四次会议，审议通过了《关于公司以 集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金以集中竞价交易方式 回购公司部分社会公众股份，用于实施员工持股计划。本次拟回购股份的价格为不超过 人民币 60 元/股（含），拟回购股份的资金总额为不低于人民币 7,500 万元（含）且不超 过人民币 15,000 万元（含）。回购期限自公司董事会审议通过回购方案之日起不超过 12 个月。 截 ...

2022 Sustainability Report and ESG Report ZHENDE MEDICAL CO.,LTD. 2022 Sustainability Report and ESG Report ZHENDE MEDICAL CO.,LTD. Contents | About This Report | 03 | | --- | --- | | About Zhende Medical | 04 | | Message from the Chairman | 05 | | - From Care to We Care | | | Key Performance on Sustainability in 2022 07 | | 02 Sustainable Development Management | ESG Strategy | 17 | | --- | --- | | ESG Management O-Chart | 19 | | Stakeholder Communication | 19 | | Analysis of Material Topics | 21 | 04 Cari ...

振德医疗用品股份有限公司 2023 年第一次临时股东大会会议材料 2023 年 9 月 19 日 振德医疗 2023 年第一次临时股东大会材料 振德医疗用品股份有限公司 2023 年第一次临时股东大会会议材料目录 第 2 页 共 6 页 二、网络投票系统及起止时间 1、网络投票系统：上海证券交易所股东大会网络投票系统 2、网络投票起止时间：自 2023 年 9 月 19 日至 2023 年 9 月 19 日。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段，即9:15-9:25，9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日 的 9:15-15:00。 三、会议方式：现场投票与网络投票相结合的方式。 一、2023 年第一次临时股东大会会议议程 二、2023 年第一次临时股东大会会议须知 三、《关于公司 2023 年半年度利润分配方案》 振德医疗 2023 年第一次临时股东大会材料 振德医疗用品股份有限公司 2023 年第一次临时股东大会会议议程 一、现场会议时间及地点 1、时间：2023 年 9 月 19 日（星期 ...

Financial Performance - For the first half of 2023, the company's operating revenue was CNY 2,306,140,255.48, a decrease of 16.66% compared to CNY 2,767,031,431.20 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 237,366,332.46, down 12.60% from CNY 271,574,153.43 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 223,033,561.78, a decline of 21.20% compared to CNY 283,036,443.39 in the same period last year[20]. - The company's revenue for the reporting period decreased by 59.43% year-on-year to 490 million RMB, primarily due to a decline in sales of isolation protective products[23]. - Excluding isolation protective products, the company's revenue increased by 16.51% year-on-year to 1.816 billion RMB[23]. - Basic and diluted earnings per share decreased compared to the same period last year, primarily due to reduced operating profit and an increase in total share capital from a previous private placement[23]. - The weighted average return on equity decreased compared to the same period last year, influenced by reduced operating profit and increased net assets from the previous private placement[23]. - The company achieved operating revenue of 2.306 billion yuan in the first half of 2023, a decrease of 16.66% year-on-year[55]. - Revenue from isolation protective products was 490 million yuan, down 59.43% year-on-year, while revenue excluding these products was 1.816 billion yuan, an increase of 16.51%[55]. - The net profit attributable to the parent company was 237 million yuan, a decrease of 12.60% year-on-year, and the net profit after deducting non-recurring gains and losses was 223 million yuan, down 21.20%[55]. Cash Flow and Assets - The net cash flow from operating activities increased by 48.43% to CNY 126,565,040.56, compared to CNY 85,271,465.41 in the previous year[20]. - The total assets at the end of the reporting period were CNY 8,177,277,700.20, reflecting a 3.55% increase from CNY 7,896,933,885.12 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were CNY 5,616,117,983.67, up 1.34% from CNY 5,541,678,060.39 at the end of the previous year[20]. - The company's cash and cash equivalents decreased by 20.15% to ¥1,656,921,010.13, accounting for 20.26% of total assets[70]. - The company's total liabilities rose to RMB 2,329,678,225.99 from RMB 2,139,939,039.32, marking an increase of approximately 8.85%[149]. - The company's equity attributable to shareholders increased to RMB 5,616,117,983.67 from RMB 5,541,678,060.39, a growth of about 1.35%[149]. Market Presence and Strategy - The company has established a marketing network covering over 8,000 hospitals across all provinces in China, including nearly 1,100 top-tier hospitals[28]. - The company has a strong presence in the international market, exporting to over 70 countries and regions, and has been ranked among the top three in China's medical dressing exports for several consecutive years[28]. - The company is focusing on market expansion through the development of innovative healthcare products tailored to meet the needs of various medical environments[31]. - The company is exploring potential acquisitions to strengthen its market position and broaden its product portfolio in the healthcare sector[31]. - The company is actively exploring international expansion and has plans to establish overseas bases to support future business growth[90]. Research and Development - The company plans to enhance its research and development efforts to introduce advanced wound care technologies in the upcoming fiscal year[31]. - The company established a new product development management system, enhancing R&D efficiency through structured market insights and customer demand management[62]. - Research and development expenses decreased to approximately ¥46 million, down 26.9% from ¥63 million in the first half of 2022[158]. - The company is focusing on technological innovation, collaborating with universities for advanced material development and achieving significant progress in wound care technology[61]. Regulatory and Compliance - The company is facing risks related to regulatory changes and industry policy shifts, which could adversely affect its operations if not adapted to promptly[88]. - The company has established a quality management system to mitigate risks associated with product quality, which is critical for patient safety, and will continue to enhance quality control capabilities through digital and automated processes[89]. - The company will strictly fulfill all commitments made prior to its listing, and if any commitments are not fulfilled, it will disclose the reasons in a timely manner through designated media[116]. Shareholder Information - The proposed cash dividend is CNY 7.50 per 10 shares, totaling CNY 199,741,320, which accounts for 84.15% of the net profit attributable to shareholders for the first half of 2023[5]. - The company reported a total of 26,286 common shareholders as of the end of the reporting period[135]. - Zhejiang Zhend Medical Holdings Co., Ltd. is the largest shareholder with 109,191,600 shares, accounting for 85.51% of the total shares[138]. Environmental Initiatives - The company has not faced any environmental penalties during the reporting period and is committed to green development and low-carbon initiatives[108]. - The company implemented various energy-saving measures, including the use of clean energy and optimization of production processes, to reduce carbon emissions[109]. - The company has established an ISO system for environmental management and is actively promoting energy conservation and emission reduction[108].

证券代码：603301 证券简称：振德医疗 公告编号：2023-026 振德医疗用品股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第三届监事会 第八次会议于 2023 年 8 月 29 日以通讯方式召开，会议通知已于 2023 年 8 月 24 日以传真、E-MAIL 和专人送达等形式提交各监事。本次会 议应表决监事 3 名，实际表决监事 3 名，符合《公司法》和《公司章 程》的有关规定，决议合法有效。 《公司 2023 年半年度报告》及《公司 2023 年半年度报告摘要》 详见 2023 年 8 月 30 日上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、审议通过《关于公司 2023 年半年度利润分配预案》，监事会 同意公司拟以实施权益分派股权登记日登记的总股本为基数（不包括 公司回购专户的股份数量），向全体股东每 10 股派发现金红利 7.50 元（含税）。截至 202 ...